m+Medelevator.RU
← Поиск публикаций
EMBO molecular medicine · 2026

Tenascin-C orchestrates radiotherapy-induced head and neck tumor regression.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Loustau Thomas, Mitrentsi Ioanna, Wang Nuohan, Spenlé Caroline, Pavlidaki Alexia, Tranchant Thibaud, Riegel Gilles, Venu Akhil, Oueidat Rime, Koch Manuel, Dumas Marion, Wack Fanny, Hirschler Aurelie, Carapito Christine, Paul Nicodème, Carapito Raphael, Mörgelin Matthias, Hansen Uwe, Azzi Joyce, Aubergeon Lucie, Salomé Nathalie, Dhaouadi Sayda, Grenot Pierre, Bouhaouala-Zahar Balkiss, La Cioppa Simona, Oertle Philippe, Izzi Valerio, Plodinec Marija, Noel Georges, Burckel Hélène, Orend Gertraud

Аннотация

Given that head and neck squamous cell carcinoma (HNSCC) patients have poor survival outcomes, a better understanding of the therapeutic benefits of ionizing irradiation (IR), the major treatment modality besides surgery, is needed. A confounding factor is the immunosuppressive tumor microenvironment determined by tenascin-C (TNC), a highly abundant extracellular matrix molecule upregulated by IR. We investigated the roles of TNC on radio-induced tumor regression in a murine oral HNSCC model expressing or lacking TNC. While tumors in a TNC-expressing host were radiosensitive, they were radioresistant in TNC genetically depleted mice. We identified fibroblast reticular cells (FRCs) as critical regulators. TNC plays a compartmentalized and dual role in regulating tumor radiosensitivity with a detrimental role in the tumor stroma opposed to an essential role in the tumor-draining lymph nodes. This is relevant as a high FRC signature and high TNC levels together correlate with shorter HNSCC patient survival. TNC-expressing FRCs may be an excellent novel target to improve radiotherapy-induced tumor eradication, as our TNC targeting MAREMO peptide reduced tumor cell numbers and plasticity upon IR.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты